• Education
  •  Download App
  • Country
    singapore
    hong kong
    malaysia
    indonesia
    thailand
    philippines
    vietnam
    india

    australia
    korea
    new zealand
The CIMS logo.
  • Home
  • Find Drugs
  • Find Drug Company
  • Diseases
  • Medical News & Updates
The CIMS logo.
  • Home
  • Find Drugs
  • Find Drug Company
  • Diseases
  • Medical News & Updates
The CIMS logo.
Home
Find Drugs
Find Drug Company
Diseases
Medical News & Updates

Other Services
 Education
  Download App
Country
singapore
hong kong
malaysia
indonesia
thailand
philippines
vietnam
australia
korea
new zealand
Account
The CIMS logo.
  1. Medical News & Updates
  2. List of Conferences
  3. ...
    • Medical News & Updates
    • List of Conferences
  4. European Association for the Study of Diabetes (EASD) Annual Meeting 2025
European Association for the Study of Diabetes (EASD) Annual Meeting 2025

European Association for the Study of Diabetes (EASD) Annual Meeting 2025

Vienna, Austria 15 September 2025 - 19 September 2025

Overweight, obesity protective against death?
Overweight, obesity protective against death?
a day ago byAudrey Abella
Audrey Abella

A large study from Denmark presented at EASD 2025 suggests that overweight and obesity may protect against death.

Overweight, obesity protective against death?
a day ago
ATTAIN-1: GLP-1RA pill confers weight-loss benefits in adults with obesity
ATTAIN-1: GLP-1RA pill confers weight-loss benefits in adults with obesity
02 Oct 2025 byJairia Dela Cruz
Jairia Dela Cruz

In adults with obesity but without diabetes, treatment with the oral small-molecule, nonpeptide glucagon-like peptide-1 receptor agonist (GLP-1RA) orforglipron yields substantial reductions in body weight, as shown in the phase III ATTAIN-1 trial.

ATTAIN-1: GLP-1RA pill confers weight-loss benefits in adults with obesity
02 Oct 2025
JAK inhibitor a new hope for new-onset T1D?
JAK inhibitor a new hope for new-onset T1D?
02 Oct 2025 byAudrey Abella
Audrey Abella

The 2-year outcomes from the phase II BANDIT* trial confirm the potential of the Janus kinase (JAK) inhibitor baricitinib for the treatment of new-onset type 1 diabetes (T1D).

JAK inhibitor a new hope for new-onset T1D?
02 Oct 2025
The CIMS logo.
  • Drugs
  • Find Drugs
  • Find Drug Company
  • CIMS Abbreviation Index
  • Diseases
  • Search Disease Information
  • Medical News & Updates
  • Latest News & Updates
  • More Services
  • Education
  • Subscribe
  • About
  • MIMS Corporate
  • Terms of Use
  • Privacy Policy
  • Feedback
Connect with CIMS
A social media brand icon.A social media brand icon.A social media brand icon.A social media brand icon.A social media brand icon.
TUV Nord ISO 9001 certification logo
CIMS Specialty main-to-v3.5.0
Copyright © 2025 CIMS Pte Ltd. All rights reserved. PRD
CIMS Logo

Sign up for Free to continue reading

Already a member?

Sign up for Free to continue reading

Already a member?

Sign up for Free to continue reading

Already a member?
Something went wrong.